(HealthDay News) — A patient-reported outcome (PRO) intervention for symptom monitoring is associated with improved overall survival for patients treated with chemotherapy for metastatic solid tumors, according to a research letter published online in the Journal of the American Medical Association. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology in Chicago.
Ethan Basch, MD, from the University of North Carolina at Chapel Hill, and colleagues examined overall survival associated with electronic patient-reported symptom monitoring vs usual care among patients initiating routine chemotherapy for metastatic solid tumors. A total of 766 participants were randomized to the usual care group or PRO group, assessed via a web-based PRO questionnaire platform. An e-mail alert was triggered to a clinical nurse when the PRO group participants reported a severe or worsening symptom.
Overall survival was assessed after 67% of the participants had died, at which time the median follow-up was 7 years. The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively (difference, five months; P =.03). The results remained significant in a multivariable model, with a hazard ratio of 0.83 (P =.04).
“Electronic patient-reported symptom monitoring may be considered for implementation as a part of high-quality cancer care,” the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
- Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 4 June 2017. doi:10.1001/jama.2017.7156